Syntonix Pharmaceuticals


	Recent Press Releases
	March 4, 2008 Biovitrum and Syntonix set to begin phase I/IIa clinical trial of long-acting recombinant Factor IXFc for the treatment of Hemophilia B January 4, 2007 BIOGEN IDEC TO ACQUIRE SYNTONIX January 23, 2006 BIOVITRUM AND SYNTONIX ENTER AGREEMENT FOR THE JOINT DEVELOPMENT AND COMMERCIALIZATION OF RECOMBINANT FACTOR IX FOR THE TREATMENT OF HEMOPHILIA October 21, 2005 SYNTONIX AND BOEHRINGER INGELHEIM ENTER COLLABORATION FOR UP TO $63 MILLION TO OPTIMIZE THERAPEUTIC PEPTIDE CANDIDATES FOR INHALATION March 31, 2005 SERONO AND SYNTONIX SIGN WORLDWIDE AGREEMENT TO DEVELOP AND COMMERCIALIZE AN INHALEABLE INTERFERON-BETA THERAPY FOR MULTIPLE SCLEROSIS May 13, 2004 SYNTONIX AND DYAX FORM JOINT ANTIBODY DISCOVERY COLLABORATION FOR AUTOIMMUNE AND INFLAMMATORY DISORDERS

	Home \| About Syntonix \| Science & Technology \| News \| Careers \| Contact Us \| Site Map Terms & Conditions of Use \| Note Regarding Forward-Looking Statements \| Privacy Policy © Biogen Idec - Biogen Idec is proud to be an Equal Opportunity Employer.